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Introduction
AA amyloidosis is a serious complication of uncon-
trolled inflammation, which if left untreated will pro-
gress to renal failure and death. Effective suppression of
the underlying inflammatory condition can halt organ
damage or even lead to improved organ function. How-
ever, in 7% of our cohort the underlying inflammatory
disease remains uncharacterised, creating a dilemma as
to the choice of empirical treatment.
Objectives
We empirically treated a small cohort of seven patients
with AA amyloidosis of uncertain cause with the IL-1
receptor antagonist anakinra.
Patients and Methods: All seven patients were under
the care of the UK National Amyloidosis Centre. Each
patient underwent extensive investigation without diag-
nosing of the underlying inflammatory condition. Each
patient subsequently underwent a trial of treatment with
anakinra. Serum SAA and renal function as well as
urine protein excretion were monitored closely, and all
patients underwent serial SAP scintigraphy to monitor
organ amyloid load.
Results
Six of seven patients experienced suppression of inflam-
matory disease activity with the median pooled pre-ana-
kinra SAA level falling from 63 mg/L (interquartile range,
IQR, 42 - 119) to 5 mg/L (IQR 4 - 7). In these six patients
this effect lasted for a median of 5.6 years, the duration of
therapy, (IQR 2.4 - 7.6). In 2 patients proteinuria improved
from 10.5 to 1.9 g/24 hr and 2 to 0.6 g/24 hr. Four patients
showed regression of amyloid deposits on SAP scintigra-
phy. Five patients reported improvement in symptoms and
one had been asymptomatic. One patient experienced no
improvement in either inflammatory markers or in symp-
toms, and treatment with anakinra was discontinued.
Conclusion
AA amyloidosis is a potentially reversible cause of renal
failure. A therapeutic trial of anakinra is worth trying as
it is potentially completely effective and has a better
safety profile than high dose corticosteroids, other anti-
cytokine or immunosuppressive drugs.
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